


# PPD Biotech Solutions has the Right NASH Experience for a Competitive Environment




The competitive landscape for NASH and NAFLD product development is rapidly growing with multiple studies already running or ready to begin. To maximize enrollment potential, it is important to get a study started as fast as possible. PPD has an experienced team of NASH/NAFLD medical and operational leaders to get your NASH study on the path to success quickly.



**38**  
NASH/NAFLD  
studies



Over  
**600** sites  
involved




**2,400**  
patients

## LEADING SITE AND PATIENT ACCESS



**350** NASH  
investigators  
IN OUR GLOBAL  
DATABASE

**Strong network of sites** WITH NASH EXPERIENCE IN THE U.S. AND EUROPE

**70K+** respondents  
WITH SELF-REPORTED FATTY-LIVER DISEASE INCLUDING CONDITIONS ASSOCIATED WITH NASH AND NAFLD IN OUR DATABASES

## Pathway to Success—From Start to Finish

Given the current development landscape and the potential need for invasive biopsies, recruitment for NASH studies faces strong competition and potentially high screen failure rates. **PPD is the right partner to help you successfully navigate these challenges from early development through post-approval.**


- NAFLD/NASH experience since 2010
- A deep understanding of the medical and regulatory requirements and the ability to provide consultation on all aspects of your study, including endpoints, protocol development and site strategy
- Rapid startup with known NASH sites and our dedicated sites with NASH experience
- Strong site relationships and experience with fast enrolling sites
- Refined patient pathway for an efficient diagnosis process including evaluation for the use of potential non-invasive assessments
- Retention planning through patient concierge services
- Sophisticated de-centralized trial solutions making challenging trials appeal to patients
- Experience with Fibroscan and imaging techniques such as MRI-PDFF and MRE, and established relationships with vendors such as Echosense, Perspectum and speciality labs for noninvasive biomarkers
- Handling of managing liver biopsies and processing with a full-service central labs support for rapid biopsy logistics and preparation

PPD Biotech solutions combines the global power and capabilities of PPD with the personal attention and flexibility not found at other CROs. Biotech or small pharma represent more than 80 percent of our NASH/NAFLD clients.

## PPD Expertise and Experience

NASH is a complicated disease that requires a broad range of expertise to operationalize. PPD can offer an end-to-end solution; from early development to commercialization. PPD's integrated NASH model offers a range of solutions and highly skilled professionals to meet all your study needs.

## PPD Integrated NASH Platform – End to End Solution



DIVERSITY AND BREADTH OF SOURCES TO DRIVE SUCCESSFUL STUDY EXECUTION AS AN EXTENSION OF **YOUR TEAM**

## PPD's NASH Experienced Staff



**270** CRAs globally with NASH experience



**40+** clinical team managers



**22+** project managers



**5** board-certified gastroenterologists

**PPD is one of the leading CROs in NASH.** Whether you are in early strategic planning or clinical development, PPD stands ready to partner with you to move your NASH treatments forward.

For more information, visit [ppdbiotech.com](http://ppdbiotech.com)

© 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 10.2022

